Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection
Able to provide informed consent
You may not be if
Pathologic evidence of pancreatic cancer
Pregnant or breast-feeding patients
Refusal or inability to tolerate scan (eg anxiety or claustrophobia)
Inability to lay flat or meet the standard requirements of traditional MRI
Hepatic function from assays obtained within 6 weeks prior to the study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
1. Bilirubin \> 1.5 x ULN
2. AST/ALT \> 2.5 x ULN
3. Albumin \< 3 g/dL
4. GGT \> 2.5 x ULN if Alkaline Phosphatase \> 2.5 x ULN
Renal function with Creatinine \> 1.5 x ULN or creatinine clearance \< 60 mL/min, from assays obtained within 6 weeks prior to study enrollment
Cardiac: congestive heart failure with New York Heart Association (NYHA) status ≥2, poorly controlled hypertension, a history of clinically significant EKG abnormalities, or myocardial infarction within 6 months of study enrollment.
Clareo Health | Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
